Compumedics turns to the US market with its brain imaging tools
A home-grown leader in sleep and neural analysis, Compumedics is tackling the burgeoning US home sleep testing market.
Stockhead
Rise and Shine: Everything you need to know before the ASX opens
Good morning! Here’s everything you need to know, and some things you don’t, before the ASX flings open its doors today.
Meteoric rise on maiden REE resource
Meteoric Resources moved as much as 36.3% higher after releasing a maiden resource estimate for the Bara do Pacu licence at its Caldeira rare earths project in Brazil.
ASX hangs onto gains… just
Despite climbing as much as 0.5pc by midday, the ASX has managed to hold onto only half of those gains, lifting just 0.27pc. Strength in the health care and financial sectors propped up the market.
ASX lifts as Trump flips; Bellevue Gold sinks
ASX inches higher on US tariff buzz, Bellevue cops a hit after a big cap raise, and HUB24 steals the spotlight with record inflows.
Trump revives global pharma tariff threat
Donald Trump again has raised the prospect of a new tariff on imported pharmaceuticals, reportedly pitched at a 25% rate.
Break it Down: Meteoric Resources
Meteoric has added tonnes to its Brazilian portfolio, making it one of the highest grade ionic clay rare earth deposits globally.
Energy and gold stocks lift ASX in early trading
Strength in the energy sector coupled with strong gold prices have lifted the ASX about 0.3pc in early morning trading.
Tony’s Takeaway: Make or break biotech
Tony turns his attention to pivotal phase 3 trials and what mix of make or break biotechs to have in your portfolio.
ASX companies building remote connectivity
Several ASX companies are developing and providing technologies for reliable communications in remote areas, including Harvest Technology.
Graphene shines as Adisyn grabs a seat
Graphene is gaining serious traction in Europe after major funding, while in Australia, Adisyn is positioning itself as a key player.
Neuren banks on ‘cascade of long-term growth’
Neuren Pharmaceuticals and US partner Acadia have been blitzing it with the Rett syndrome treatment Daybue, exceeding expectations of two years ago when the drug was approved in the US.
Koonenberry glows as gold holds firm above $3200
Koonenberry Gold has lifted 30pc on broad, high-grade results from the second diamond hole at Sunnyside prospect.
ASX closes day firmly in the green
After last week’s chaos investors are breathing a sigh of relief today, buying into a marginally calmer market and driving the ASX up 1.5pc.
Break it Down: EBR Systems
EBR Systems lands FDA approval for Wise CRT system, a world first solution proving pacing options for the left side of the heart.
ASX leaps, Neuren jumps, GGE leads small caps
ASX jumps on tariff relief, Wall Street ends strongly despite “Sell America” talk and Neuren and GGE take off.
EBR wins US approval for game-changing heart device
The US Food & Drug Administration has approved EBR System’s leadless pacemaker WISE, the only device able to deliver left-ventricle stimulation.
Break it Down: Nordic Resources
Nordic Resources has completed an oversubscribed placement to advance its new gold and copper asset in Finland.
Miners lift ASX as US markets post weekly gain
Check out the top 10 winners and losers on the ASX as miners buoy the market. US and Asian markets lifted over the past five days despite tariff chaos.
Small cap ASX utilities could thrive from tariffs
Trump’s tariffs are shaking things up worldwide, but small-cap Aussie utilities might just sail through and even come out ahead.
Original URL: https://www.news.com.au/finance/business/stockhead/page/2